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Abstract
Background: Liver or kidney transplant recipients are at a higher risk of developing tuberculosis (TB) than general
population. We aimed to clarify the incidence density of and risk factors for TB in liver or kidney transplant
recipients in the present study.
Methods: All patients with TB following liver or kidney transplantation were investigated retrospectively at the
Third Xiangya Hospital, Central South University, Changsha, China. The incidence density of TB was calculated. We
performed a nested case–control study (1:1) to investigate by univariate and multivariate logistic regression analysis
the potential risk factors for TB.
Results: From January 2000 to August 2013, 1748 kidney and 166 liver transplant recipients were performed at a
university teaching hospital. Among the 1914 recipients, 45 cases (2.4%) of TB were reported. The incidence density
was 506 cases per 105 patient-years in kidney or liver transplant recipients, which was 7 times higher than in
the general Chinese population (around 70 cases per 105 person-years). The median time to develop TB was
20.0 months (interquartile ratio: 5.0-70.0). The receipt of a graft from a cadaveric donor (odds ratio [OR] = 3.7; 95%
confidence interval [CI] = 1.4-10.0; P = 0.010) and the preoperative evidence of latent TB (OR = 6.8; 95% CI = 2.0-22.7;
P = 0.002) were identified as two risk factors for developing TB in liver or kidney transplant recipients.
Conclusions: The incidence density of TB among liver or kidney transplant recipients was much higher than in the
general Chinese population. Recipients receiving a graft from a cadaveric donor and the preoperative evidence of
latent TB were two major risk factors for developing TB in liver or kidney transplant recipients.
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Background
Tuberculosis (TB) remains a major global health problem.
The incidence rate of TB among transplant recipients re-
lies on its incidence rate in the general population. Recipi-
ents following organ transplantation are placed at a 20-74
times higher risk for developing TB than the general
population [1-5]. TB in solid organ transplant (SOT)
recipients is a challenge because of its atypical and extra-
pulmonary presentations, metabolic interactions between
the immunosuppressive drugs and the drugs used to treat
TB, the side effects from long-term treatment of TB, as
well as a high mortality rate [1,6-9]. Among transplant
recipients, the development of TB is mainly caused by
reactivation of an old dormant infection [10-12]. China is
one of the world’s 22 countries with the highest burden of
TB and has great liver and kidney transplant activity. We
aimed to clarify the incidence density of and risk factors




The study protocol, which included participants provid-
ing written consent prior to the study, was approved by
the Third Xiangya Hospital, Central South University,
Medical Ethical Committee.
Patient population and definitions
From January 2000 to August 2013, all liver or kidney
transplant recipients with TB were identified using the
electronic medical record system at the Third Xiangya
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Hospital, Central South University, Changsha, China; their
clinical and demographic characteristics were carefully
reviewed. A nested case-control study was then performed
to reveal the association between risk factors and TB fol-
lowing liver or kidney transplantation.
A patient was considered to have TB if Mycobacterium
tuberculosis was isolated by culture, acid-fast bacilli were
present on the smear, polymerase chain reaction was
positive for Mycobacterium tuberculosis, or caseating
granulomas were found in histopathology [13,14]. Pa-
tients whose TB was diagnosed and treated on the basis
of clinical or radiological suspicion were excluded from
the study. Old TB lesions on chest x-ray were defined as
fibrotic pulmonary lesions in upper lobes or anywhere
in the lung. Incidence density was calculated by the num-
ber of new cases divided by the population-time (person-
years of observation) in which they occur. Controls
were randomly chosen at a ratio of 1:1 from recipients
who had liver or kidney transplantation not complicated
by TB at the same time as the cases. Subjects in the con-
trol group were well matched to the cases with regard
to gender, transplant organ type, and date of trans-
plantation (±1 year). Clinical records of liver or kidney
recipients with TB were analyzed including demographic
characteristics, diabetes mellitus, etiology of renal or
hepatic insufficiency, chronic hepatitis B or C virus in-
fection, previous transplantation, pure protein derivative
(PPD) skin test, transplant organ type, graft origin,
immunosuppressive regimen, rejection episode within
6 months prior to TB, cytomegalovirus (CMV) infec-
tion and major infections within 3 months prior to
TB, TB sites, diagnostic methods, time of TB onset, and
body temperature at the onset of TB. CMV infection was
defined as biopsy-proven CMV disease or reactivation
with positive PCR detection of CMV DNA/positive
antigen detection of PP65. Patients who entered the co-
hort most recently were followed up for at least 3 months
after transplantation.
Statistical analysis
Results for continuous variables with a normal distribu-
tion were presented as mean ± standard deviation (SD)
and compared using Student’s t-test. Chi-square analysis
or Fisher’s exact test was used to compare categorical
data. Discrete variables were expressed as percentages.
Factors associated with TB on a univariate analysis with
P < 0.05 were introduced into a multivariate logistic re-
gression analysis. Odds ratio (OR) with 95% confidence
interval (CI) was calculated to assess the association of po-
tential risk factors with the development of TB. A two-
tailed value of P < 0.05 was established as the threshold
of statistical significance. Data analyses were performed
with the statistical package SPSS, version 17.0 (SPSS Inc.,
Chicago, Illinois, USA).
Results
From January 2000 to August 2013, a total of 1914 kid-
ney and liver transplants were performed at the Third
Xiangya Hospital (1748 kidney and 166 liver transplants).
Patients were followed for a median 6.2 years post-
transplant (interquartile range 2.6-11.8), for a total 725
person-years of follow up. During this time 45 patients de-
veloped active TB, corresponding to an incidence density
of 506 per 105 person-years. Among these 45 cases with
TB, there were 34 men and 11 women; 43 received kidney
transplants and 2 received liver transplants. The mean age
of TB patients at transplantation was 37.9 (37.9 ± 10.0)
years. Pulmonary TB was the most common form of the
disease and was diagnosed in 28 patients (62.2%). The dis-
ease was disseminated in 13 (28.9%) patients. Extrapulmon-
ary TB occurred in four (8.9%) patients (TB lymphadenitis,
TB peritonitis, TB spondylitis, and tuberculocele in one
patient each). The median interval from the date of trans-
plantation to the development of TB was 20.0 months
(interquartile ratio: 5.0-70.0). Of the TB cases, 17 (37.8%)
appeared within the first posttransplant year. Of the 45
cases, all underwent preoperative chest x-ray, 36 PPD test,
and 4 interferon gamma release assay (IGRA) test. Seven-
teen patients showed evidence of latent TB. Old TB le-
sions on chest x-ray existed in 10 patients, the PPD test
result was positive for 10 patients, and IGRA test was
positive for 1 patient (Table 1). Of the 45 controls, all
underwent preoperative chest x-ray, 16 PPD test, and 1
IGRA test. Five showed evidence of latent TB. Screening
of latent TB was, but treatment of latent TB was not, the
standard of care in our setting. Thus, none of cases and
controls with the present of evidence of latent TB received
prophylaxis with isoniazid prior to, or in fact after trans-
plantation. Mycobacterium tuberculosis cultures were
available in 38 out of 45 cases (84.4%). Of these 38 cases,
23 had a positive culture (60.5%). Of the 45 patients with
TB, 4 patients died, and of these deaths, 2 (50.0%) were
due to disseminated TB.
Eighteen cases (40.0%) had CMV infection within
3 months prior to TB presentation. All 7 cases with a
history of diabetes mellitus (15.6%) underwent a kid-
ney transplant. Six cases had hepatitis B and 4 hepatitis
C virus infection prior to transplantation. The general
characteristics of these 45 kidney or liver transplant pa-
tients with TB were described in Table 1.
Table 2 described the clinical characteristics of kidney
or liver transplant recipients with TB compared with
controls using the univariate and multivariate analysis.
The univariate analysis showed that CMV infection within
3 months prior to TB (P = 0.012), the receipt of a graft
from a cadaveric donor (P = 0.031) and the preoperative
evidence of latent TB (P = 0.003) were more frequent in
the case group, but age, gender, immunosuppressive drugs
received, diabetes mellitus, history of rejection or use of
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Table 1 Main characteristics of 45 kidney or liver
transplant patients with TB
Characteristics No. (%) (n = 45)
Age, mean years ± SD 37.9 ± 10.0
Gender, number of male/number of female 34/11
Temperature of 39°C or greater 15 (33.3)
Primary kidney or liver disease, n (%)
Glomerulonephritis 33 (73.3)
Diabetes 7 (15.6)
Adult polycystic disease 1 (2.2)
Liver cirrhosis 2 (4.4)
Other 2 (4.4)




The type of transplantation, n (%)
Liver 2 (4.4)
Kidney 43(95.6)
Two or more transplants 4 (8.9)
Immunosuppressive drugs, n (%)
Methylprednisolone 45 (100)
Prednisone 45 (100)




Antilymphocytic or antithymocytic agents 7 (15.6)
Time of TB diagnosis posttransplant, no. of cases (%)
< 7 mo 13 (28.9)
7th to 12th mo 4 (8.9)
> 12 mo 28 (62.2)
Evidence of latent TB (No. of positive
test/No. of patients tested)
17 (37.8)
Untreated TB lesion in chest plain radiograph 10/40 (25.0)
Preop PPD test positive 10/36 (27.8)
Preop IGRA test positive 1/4 (25.0)
Recent TB contact history 1/45 (2.2)




Diagnostic modalities (No. of positive
test/No.of patients tested)
Culture positive 23/38 (60.5)
Smear positive 15/36 (41.7)
PCR positive 12/20 (60.0)
Table 1 Main characteristics of 45 kidney or liver
transplant patients with TB (Continued)
Pathology only 3/3 (100.0)
IGRA positive 6/30 (20.0)
PPD positive 5/20 (25.0)
Diabetes mellitus, n (%) 7 (15.6)
Rejection within 6 months prior to TB, n (%) 15 (33.3)
CMV infection within 3 months prior to TB 18 (40)
HCV, HBV 10 (22.2)
Major infection within 3 months prior to TB 13 (28.9)
ESR at the onset of TB > 40 mm/h 18 (40.0)
Creatinine at the onset of TB > 2 mg/dl 10 (22.2)
Crude mortality 4 (8.9)
1Cases with extrapulmonary TB in 4 patients, TB lymphadenitis, TB peritonitis,
TB spondylitis, and tuberculocele in 1 patient each.
TB, tuberculosis; SD, standard deviation; DCD, donation after cardiac death;
PPD, pure protein derivative; IGRA, interferon gamma release assay; PCR,
polymerase chain reaction; CMV, cytomegalovirus; HCV, Hepatitis C Virus; HBV,
Hepatitis B Virus; ESR, Erythrocyte Sedimentation Rate.
Table 2 Clinical characteristics of kidney or liver







Age, mean years ± SD 37.9 ± 10.0 37.8 ± 10.0 0.974
Gender, number of male/number
of female
34/11 34/11 -
Donor type, Deceased/the others 32/13 22/23 0.031
The type of transplantation,
Liver/Kidney
2/43 2/43 -
Two or more transplants 4 4 1.000
Tacrolimus/Cyclosporine 34/10 34/11 0.849
Use of antilymphocytic agents 7 14 0.081
Preoperative evidence of latent TB1 17 5 0.003
Diabetes mellitus 7 7 1.000
Rejection, n (%) 15 13 0.649
CMV infection 18 5 0.012
HCV, HBV 10 10 1.000
Major infection2 13 16 0.499
Multivariate analysis OR (95% CI)
Graft from a cadaveric donor 3.7 (1.4-10.0) 0.010
Preoperative evidence of latent TB 6.8 (2.0 - 22.7) 0.002
1Including positive PPD or IGRA, untreated TB lesion on plain chest radiograph,
recent TB contact history.
2Including pneumonia,bloodstream infections,urinary tract infection or
intracranial infection.
TB, tuberculosis; SD, standard deviation; DCD, donation after cardiac death;
CMV, cytomegalovirus; HCV, Hepatitis C Virus; HBV, Hepatitis B Virus; ESR,
Erythrocyte Sedimentation Rate; OR, odds ratio; CI, confidence interval.
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antilymphocytic or antithymocytic agents prior to TB,
hepatitis B or C virus infection, and the occurrence
of major infections prior to diagnosis of TB did not
differ between cases and controls (Table 2). The po-
tential risk factors that were consistently retained in
the multiple logistic regression analysis were the receipt
of a graft from a cadaveric donor (OR = 3.7; 95% CI = 1.4-
10.0; P = 0.010) and the preoperative evidence of latent TB
(OR = 6.8; 95% CI = 2.0-22.7; P = 0.002).
Discussion
TB is one of the most important opportunistic infections
encountered posttransplantation [9,11,15,16]. The inci-
dence rate of TB in SOT recipients ranged from 1.2% to
15% [1]. According to the 2013 WHO global TB report,
China ranks as the second among the world’s 22 high bur-
den countries with a TB incidence around 1.4 million,
and the incidence density of TB in general Chinese popu-
lation was around 70 cases per 105 person-years in 2012
[17]. The incidence density of TB in our present study was
506 per 105 patient-years, indicating that a liver or kidney
transplant recipient had 7-fold higher risk of developing
TB than a person from the general Chinese population.
Previous studies [9,11,13] had demonstrated that the
majority of SOT patients developed TB within 1 year of
operation. In the present study, we found that less than
half (37.8%) of all TB cases appeared within the first post-
transplant year. The possible explanation for this result
was that in the current study, the subjects with TB mainly
comprised kidney transplant recipients (43 out of 45 TB
cases). Kidney transplant recipients were less immunosup-
pressed and lived longer than other transplant recipients,
which could have accounted for the later occurrence of
TB in these population [9].
Pre-transplantation parameters that could predict the
development of TB would be extremely valuable since
the classic presentation of TB was atypical among trans-
plant recipients. Various variables previously described
in the literature as risk factors for TB include: age, racial
background, blood group, diabetes mellitus, previous ex-
posure to TB, protein-calorie malnutrition, hemodialysis
for longer periods, chronic liver disease (in kidney trans-
plant), type of transplantation and immunosuppressive
agents, allograft rejection, chronic graft dysfunction, hepa-
titis C virus or CMV infection, and concomitant oppor-
tunistic infections [9,11,14,15,18-27].
There was an understandably high rate of pre-existing
positive PPD and chest x-ray changes in our study popu-
lation (37.8% in cases vs. 11.1% in controls), accordant
with Basiri A and colleagues [14] who reported that
64.2% of patients and 0.2% of controls had radiological
evidence compatible with tuberculosis. In view of this,
we would expect high rates of transmission of TB after
renal or liver transplantation. Actually, an incidence
2.2% (1/45) of donor-derived transmission of TB was
found in the current study, consistent with other studies
[9,28] which suggested that in American, donor-derived
transmission of TB accounted for < 5% of TB cases after
SOT. We found in the present study that the preopera-
tive evidence of latent TB was an independent risk factor
for posttransplant TB, similar to other studies [14,18],
but having major discrepancy from some reports [25,29]
that did not confirm the association between latent TB
and risk of TB. Although some transplant centers have
observed a low likelihood of the development of TB in
untreated PPD-positive transplant recipients without other
risk factors for TB [3,30-32], several existing guidelines
made recommendations that all patients awaiting organ
transplant should be screened for latent TB infection, and
that patients diagnosed with latent TB infection should be
ideally treated pretransplant or if time does not permit,
therapy should be started or completed posttransplant
[19,33-35]. Our finding highlighted the importance of
treatment of latent TB infection, which was recommended
by other studies [11,29,36,37].
Another finding of ours was that the receipt of a graft
from a cadaveric donor was independently associated
with an increased risk for developing TB following liver
or kidney transplantation. The reasons for this result
were not clear. One possible explanation was that the
remainder of the donors mainly comprised living rela-
tive donors (12 out of 13 non-cadaveric donors). Pro-
tective immunity against TB infection was a cell-mediated
process [38,39]. The ability of T-cell to inhibit the growth
of mycobacteria was impaired more in patients receiving a
graft from a cadaveric donor than in patients receiving a
graft from a living relative donor, because more immuno-
suppressive agents must be administrated against acute
cellular rejection. There were many other factors contrib-
uting to predisposing SOT recipients to TB, such as
higher rates of cadaveric donor active or latent TB infec-
tion leading to a certain incidence rate of donor-derived
transmission of TB [9,28]. Thus, patients receiving a graft
from a cadaveric donor might be at a higher risk of TB.
Our study contributed to the literature by demonstrating,
for the first time, that the receipt of a graft from a cadav-
eric donor could be a risk factor for increased TB among
liver or kidney recipients. The results of this study might
be useful in avoiding TB in liver or kidney transplant
recipients.
In short, we found the incidence density of TB to be
7-fold higher among liver or kidney transplant recipients
than among the general Chinese population. The receipt
of a graft from a cadaveric donor rather than other sources
of donors, and the preoperative evidence of latent TB were
significant risk factors for developing TB in liver or kidney
transplant recipients. Nevertheless, the small sample size
and the retrospective nature of the study design were two
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major limitations in the present study. Clinicians should
pay more attention to these risk factors and properly ad-
minister preventive therapy to improve the outcome of
liver or kidney transplant recipients.
Conclusions
The incidence density of TB among liver or kidney trans-
plant recipients was much higher than in the general
Chinese population. Recipients receiving a graft from a ca-
daveric donor and the preoperative evidence of latent TB
were two major risk factors for developing TB in liver or
kidney transplant recipients.
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